Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone44-0-12-3544-2780
Debt
Current Ratio2.23
Quick Ratio2.12
Price-To-Earnings
Sales & Book Value
Annual Sales$103.08 million
Price / Sales3.81
Price / Cash FlowN/A
Price / Book4.35
Profitability
Net Income$-32,880,000.00
Net Margins-12.51%
Return on Assets-24.11%
Miscellaneous
Employees457
OptionableNot Optionable
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings results on Friday, November, 9th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.14. The company had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. Oxford Immunotec Global's revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.70) earnings per share. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
3 analysts have issued 12-month target prices for Oxford Immunotec Global's stock. Their predictions range from $15.00 to $19.00. On average, they expect Oxford Immunotec Global's share price to reach $17.00 in the next year. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.
What is the consensus analysts' recommendation for Oxford Immunotec Global?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.
Has Oxford Immunotec Global been receiving favorable news coverage?
Headlines about OXFD stock have been trending somewhat positive on Wednesday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Meridian Bioscience (VIVO), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Arca Biopharma (ABIO) and Fluoropharma Medical (FPMI).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
- Mr. Richard M. Altieri, Chief Financial Officer (Age 59)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $14.88.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $387.77 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.
What is Oxford Immunotec Global's official website?
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
